These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 2503259)

  • 1. Toxicity of high-dose ifosfamide in children.
    Davies SM; Pearson AD; Craft AW
    Cancer Chemother Pharmacol; 1989; 24 Suppl 1():S8-10. PubMed ID: 2503259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Etoposide, ifosfamide, and cisplatin therapy for refractory childhood solid tumors. Response and toxicity.
    van Hoff J; Grier HE; Douglass EC; Green DM
    Cancer; 1995 Jun; 75(12):2966-70. PubMed ID: 7773949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose ifosfamide with mesna uroprotection: a phase I study.
    Elias AD; Eder JP; Shea T; Begg CB; Frei E; Antman KH
    J Clin Oncol; 1990 Jan; 8(1):170-8. PubMed ID: 2104923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I trial of ifosfamide, mesna, and cisplatin in advanced non-small cell lung cancer. A cancer and leukemia group B study.
    Graziano SL; Herndon JE; Richards F; DiFino S; Modeas C; Duggan DB; Green MR
    Cancer; 1993 Jul; 72(1):62-8. PubMed ID: 8389667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules.
    Antman KH; Elias A; Ryan L
    Semin Oncol; 1990 Apr; 17(2 Suppl 4):68-73. PubMed ID: 2110386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ifosfamide in pediatric malignant solid tumors.
    Pratt CB; Douglass EC; Etcubanas EL; Goren MP; Green AA; Hayes FA; Horowitz ME; Meyer WH; Thompson EI; Wilimas JA
    Cancer Chemother Pharmacol; 1989; 24 Suppl 1():S24-7. PubMed ID: 2503257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ifosfamide continuous infusion without mesna. A phase I trial of a 14-day cycle.
    Lokich I; Anderson N; Bern M; Moore C
    Cancer; 1991 Feb; 67(4):883-5. PubMed ID: 1899352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma.
    Stuart-Harris RC; Harper PG; Parsons CA; Kaye SB; Mooney CA; Gowing NF; Wiltshaw E
    Cancer Chemother Pharmacol; 1983; 11(2):69-72. PubMed ID: 6414732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ifosfamide tolerance in osteosarcoma patients previously treated with cis-diamminedichloroplatinum-II: renal, hematologic, and neurologic observations.
    Canpolat C; Pearson P; Robertson R; Jaffe N
    Med Pediatr Oncol; 1996 Jan; 26(1):36-47. PubMed ID: 7494510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for ifosfamide nephrotoxicity in children.
    Skinner R; Pearson AD; English MW; Price L; Wyllie RA; Coulthard MG; Craft AW
    Lancet; 1996 Aug; 348(9027):578-80. PubMed ID: 8774570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support.
    Elias AD; Ayash LJ; Eder JP; Wheeler C; Deary J; Weissman L; Schryber S; Hunt M; Critchlow J; Schnipper L
    J Clin Oncol; 1991 Feb; 9(2):320-7. PubMed ID: 1846407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral ifosfamide-mesna: a clinical investigation in advanced non-small-cell lung cancer.
    Manegold C; Bischoff H; Fischer JR; Löchner S; Peukert M; Schmähl A; Drings P
    Ann Oncol; 1992 Nov; 3(9):723-6. PubMed ID: 1333266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of ifosfamide in combination with etoposide and cisplatin in the treatment of extensive small cell lung cancer.
    Evans WK; Stewart D; Logan D; Maroun J; Goss G; Shepherd FA; Latreille J; Warner E; Dahrouge S
    Semin Oncol; 1992 Dec; 19(6 Suppl 12):51-6. PubMed ID: 1336622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study of ifosfamide with Mesna given daily for 3 consecutive days to children with malignant solid tumors.
    Pratt CB; Meyer WH; Douglass EC; Bowman L; Wilimas J; Ochs J; Marina N; Avery L; Thompson EI
    Cancer; 1993 Jun; 71(11):3661-5. PubMed ID: 8490914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence.
    Patel SR; Vadhan-Raj S; Papadopolous N; Plager C; Burgess MA; Hays C; Benjamin RS
    J Clin Oncol; 1997 Jun; 15(6):2378-84. PubMed ID: 9196153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous 5-day infusion of ifosfamide with mesna in inoperable pancreatic cancer patients: a phase II study.
    Cerny T; Martinelli G; Goldhirsch A; Terrier F; Joss R; Fey MF; Brunner KW; Küpfer A
    J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S135-8. PubMed ID: 1795002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ifosfamide treatment as a 10-day continuous intravenous infusion.
    Keizer HJ; Ouwerkerk J; Welvaart K; van der Velde CJ; Cleton FJ
    J Cancer Res Clin Oncol; 1995; 121(5):297-302. PubMed ID: 7768968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of ifosfamide in children with malignant solid tumors.
    Pratt CB; Horowitz ME; Meyer WH; Etcubanas E; Thompson EI; Douglass EC; Wilimas JA; Hayes FA; Green AA
    Cancer Treat Rep; 1987 Feb; 71(2):131-5. PubMed ID: 3100034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of a 24-h continuous infusion of ifosfamide/mesna in acute lymphoblastic leukemia.
    Otero JC; Solidoro A; Casanova L; Vallejos C; Rodriguez W
    J Exp Ther Oncol; 1996 Mar; 1(2):84-7. PubMed ID: 9414391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ifosfamide with mesna uroprotection and etoposide in recurrent, refractory acute leukemia in childhood. A Pediatric Oncology Group Study.
    Bernstein ML; Whitehead VM; Devine S; Grier H; Kung F; Krischer J; Dreyer Z; Bell B; Land V; Buchanan GR
    Cancer; 1993 Sep; 72(5):1790-4. PubMed ID: 8348510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.